Analysis of the treatment effect of percutaneous balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension
-
摘要:
目的 评价球囊扩张成形术(BPA)治疗慢性血栓栓塞性肺动脉高压(CTEPH)的有效性和安全性。 方法 选择2019年10月—2022年6月郑州大学第一附属医院确诊CTEPH接受BPA手术的8例住院患者,收集患者的基本临床特征,观察BPA手术前后血流动力学指标、心脏结构改善情况及手术并发症事件的发生情况。 结果 女性患者5人,男性患者3人。发病时年龄为(55.25±10.45)岁,由急性肺栓塞进展至CTEPH形成时间为(10.87±6.10)个月,随访时长为(255.50±149.71)d,共进行BPA手术46次,出现咯血并发症1次发生于大动脉炎患者,平均BPA次数为(5.75±3.57)次。BPA术后肺动脉平均压由(92.25±33.59)mmHg(1 mmHg=0.133 kPa)降至(53.87±27.58)mmHg(P=0.022);氨基末端脑钠肽前体、心输出量、心指数、三尖瓣反流速度、左心室舒张末期容积、纽约心脏病学会心功能分级均明显改善(均P < 0.05)。比较患者BPA手术前、出院前及随访时的心脏结构指标发现,右心室直径、左心室直径和右心房上下径均有改善(均P < 0.05)。 结论 BPA手术作为一种新型手术方案,在CTEPH患者中应用后可改善血流动力学指标和心脏结构,同时并发症较少。 -
关键词:
- 慢性血栓栓塞性肺动脉高压 /
- 球囊扩张成形术 /
- 急性肺栓塞
Abstract:Objective To evaluate the efficacy and safety of balloon pulmonary angioplasty (BPA) in a cohort of patients with pulmonary hypertension due to chronic thrombotic and/or embolic disease (CTEPH). Methods From October 2019 to June 2022, 8 patients diagnosed with CTEPH at the First Affiliated Hospital of Zhengzhou University underwent BPA surgery. The basic clinical characteristics of the patients were collected, and the hemodynamic indexes, improvement of cardiac structure, and surgical complications were observed. Results There were 5 female and 3 male patients. The mean age at presentation was (55.25±10.45) years, and the mean progressed period of CTEPH was (10.87±6.10) months, and the average follow-up duration was (255.50±149.71) days. A total of 46 BPA operations were performed, with one hemoptysis complication occurred in a patient with Takayasu' s arteritis, and the average number of BPA operations was (5.75±3.57) times. Mean pulmonary artery pressure after BPA decreased from (92.25±33.59) mmHg (1 mmHg=0.133 kPa) to (53.87±27.58) mmHg (P=0.022). NT-proBNP, cardiac output, cardiac index, tricuspid regurgitation velocity, EDV and NYHA were significantly improved (all P < 0.05). When cardiac structural parameters were compared before BPA surgery, before discharge and at follow-up, right ventricular diameter, left ventricular diameter, and right atrial upper and lower diameter were all improved (all P < 0.05). Conclusion BPA is a new surgical technique that can improve hemodynamic indexes and cardiac structure in CTEPH patients with fewer complications. -
表 1 8例CTEPH患者行BPA前一般临床资料
Table 1. General clinical characteristics of 8 patients with CTEPH prior to BPA
编号 年龄(岁) 性别 CTEPH进展时程(月) 合并症 PAH药物治疗方案 BPA次数 择期手术次数 随访时长(d) 1 52 女性 10 中度三尖瓣关闭不全 安立生坦,西地那非 3 1 217 2 40 女性 5 左下肢静脉血栓 安立生坦,利奥西呱 2 1 198 3 62 男性 12 3级高血压,肺气肿 安立生坦,利奥西呱 8 3 271 4 66 男性 11 重度三尖瓣关闭不全,冠心病 贝前列素那,安立生坦,西地那非 7 2 31 5 68 女性 12 冠心病支架术后,3级高血压,糖尿病 安立生坦,利奥西呱 9 3 207 6 44 女性 24 大动脉炎,右肾动脉狭窄支架术后,甲状腺功能亢进症 西地那非 5 3 301 7 61 男性 9 心房颤动,下肢静脉曲张 利奥西呱 11 4 252 8 49 女性 4 下肢静脉血栓,中度三尖瓣关闭不全 未使用PAH药物治疗方案 1 1 566 注:编号6患者出现一次手术失败情况。 表 2 8例CTEPH患者BPA手术前和出院前血流动力学指标比较
Table 2. Comparison of hemodynamic parameters before and at discharge in 8 patients with CTEPH undergoing BPA
项目 手术前 出院前 统计量 P值 肺动脉平均压(x±s, mmHg) 92.25±33.59 53.87±27.58 3.620a 0.022 NT-proBNP[M(P25, P75), pg/mL] 5 300.72(1 136.15,5 685.00) 377.29(74.98,946.00) -2.201b 0.028 心输出量(x±s, L/min) 4.60±1.71 5.88±1.99 -2.923a 0.027 心指数[x±s, L/(min·m2)] 2.79±1.13 3.51±1.23 -3.013a 0.024 肺动脉环径(x±s, mm) 24.28±3.09 23.57±3.20 0.420a 0.689 三尖瓣反流速度(x±s, m/s) 4.41±0.93 3.22±0.93 4.095a 0.005 EDV(x±s, mL) 66.57±26.96 89.71±24.28 -3.065a 0.022 ESV(x±s, mL) 22.78±8.94 30.35±10.57 -2.177a 0.072 LVEF(x±s, %) 64.37±4.47 66.00±5.63 -0.604a 0.565 NYHA心功能分级(Ⅲ级/Ⅳ级,例) 0/8 6/2 5.143c 0.016 注:a为t值,b为Z值,c为χ2值。 表 3 8例CTEPH患者BPA手术前、出院前和随访时心脏结构测量结果比较(x±s,mm)
Table 3. Comparison of cardiac structural measurements before, at discharge, and during follow-up in 8 patients with CTEPH undergoing BPA (x±s, mm)
项目 手术前 出院前 随访时 F值 P值 右心室直径 26.42±7.43 20.75±4.83 18.57±6.39 5.982 0.016 左心室直径 38.57±4.99 43.37±4.62 42.00±4.72 8.013 0.028 右心房左右径 46.14±9.70 38.12±7.56 37.14±6.64 1.914 0.241 右心房上下径 57.71±8.97 49.12±8.77 47.00±10.47 6.191 0.014 -
[1] PAPAMATHEAKIS D G, POCH D S, FERNANDES T M, et al. Chronic thromboembolic pulmonary hypertension: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 76(18): 2155-2169. doi: 10.1016/j.jacc.2020.08.074 [2] 朱林, 卢冉, 郭飞. 多层螺旋CT多参数对急性肺动脉栓塞危险分层的效果评估[J]. 中华全科医学, 2021, 19(12): 2093-2097. doi: 10.16766/j.cnki.issn.1674-4152.002245ZHU L, LU R, GUO F. Assessment of the effectiveness of multi-slice spiral CT multiparameter for risk stratification of acute pulmonary embolism[J]. Chinese Journal of General Practice, 2021, 19(12): 2093-2097. doi: 10.16766/j.cnki.issn.1674-4152.002245 [3] POCH D, MANDEL J. Pulmonary hypertension[J]. Ann Intern Med, 2021, 174(4): ITC49-ITC64. DOI: 10.7326/AITC202104200. [4] 王颖, 王孝高, 宋涛, 等. 肺动脉栓塞合并急性下肢深静脉血栓形成的类型比例分析与解读[J]. 中华全科医学, 2018, 16(1): 107-109. doi: 10.16766/j.cnki.issn.1674-4152.000031WANG Y, WANG X G, SONG T, et al. Analysis and interpretation of the type of pulmonary embolism complicated with deep venous thrombosis of the lower extremities[J]. Chinese Journal of General Practice, 2018, 16(1): 107-109. doi: 10.16766/j.cnki.issn.1674-4152.000031 [5] HUMBERT M, KOVACS G, HOEPER M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38): 3618-3731. doi: 10.1093/eurheartj/ehac237 [6] GALIÈ N, HUMBERT M, VACHIERY J L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J, 2016, 37(1): 67-119. doi: 10.1093/eurheartj/ehv317 [7] GHOFRANI H A, KIM N H. Medical and interventional therapies for inoperable CTEPH: a necessary combination?[J]. Lancet Respir Med, 2022, 10(10): 926-927. doi: 10.1016/S2213-2600(22)00227-2 [8] 丁媛, 龚娟妮, 王剑锋, 等. 肺动脉球囊扩张成形术治疗慢性血栓栓塞性肺动脉高压的疗效观察[J]. 中华结核和呼吸杂志, 2020, 43(12): 1049-1054. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYI201912012.htmDING Y, GONG J N, WANG J F, et al. A retrospective study of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2020, 43(12): 1049-1054. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYI201912012.htm [9] 赵智慧, 王勇, 罗勤, 等. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的安全性和有效性分析[J]. 中国循环杂志, 2019, 34(6): 563-567. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202307010.htmZHANG Z H, WANG Y, LUO Q, et al. Safety and efficacy of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension[J]. Chinese Circulation Journal, 2019, 34(6): 563-567. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202307010.htm [10] 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202303020.htmPulmonary embolism and pulmonary vascular diseases group of Chinese Thoracic Society, Chinese Association of Chest Physicians pulmonary embolism and pulmonary vascular disease working committee, National pulmonary embolism and pulmonary vascular disease Prevention and Treatment Cooperation group, et al. Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Artery Hypertension (2021 Edition)[J]. National Medical Journal of China, 2021, 101(1): 11-51. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202303020.htm [11] INAMI T, KATAOKA M, SHIMURA N, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty[J]. JACC Cardiovasc Interv, 2013, 6(7): 725-736. [12] ZOPPELLARO G, BADAWY M R, SQUIZZATO A, et al. Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis[J]. Circ J, 2019, 83(8): 1660-1667. [13] 赵丹, 龚娟妮, 唐小红, 等. 肺动脉球囊扩张成形术治疗慢性血栓栓塞性肺动脉高压患者的疗效及不良反应观察[J]. 中国医刊, 2019, 54(12): 1308-1311. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYI201912012.htmZHAO D, GONG J N, TANG X H, et al. Observation on the therapeutic effect and adverse reactions of balloon pulmonary angioplasty treating patients with chronic thrombotic pulmonary hypertension[J]. Chinese Journal of Medicine, 2019, 54(12): 1308-1311. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYI201912012.htm [14] 江莹, 岳雯静, 吴慧玲, 等. 肺动脉高压专科护士角色职责研究的范围综述[J]. 中国护理管理, 2023, 23(2): 241-246. https://www.cnki.com.cn/Article/CJFDTOTAL-GLHL202302017.htmJAING Y, YUE W J, WU H L, et al. Role development and role responsibilities of clinical nurse specialists in Pulmonary Hypertension: a scoping review[J]. Chinese Nursing Management, 2023, 23(2): 241-246. https://www.cnki.com.cn/Article/CJFDTOTAL-GLHL202302017.htm [15] EJIRI K, AKAGI S, ITO H. Woman in her 50s with pulmonary hypertension associated with Takayasu arteritis[J]. JAMA Cardiol, 2023, 8(8): 792. [16] EZZEDDINE F M, HURST P D, BOOKWALTER C A. Takayasu arteritis[J]. Mayo Clin Proc, 2023, 98(7): 1033-1034. [17] MAHMUD E, ANG L. Time to standardize definitions for the success and complications of balloon pulmonary angioplasty: a quality imperative[J]. JACC Cardiovasc Interv, 2023, 16(8): 984-985. [18] RIVERS-BOWERMAN M D, ZENER R, JABERI A, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: new horizons in the interventional management of pulmonary embolism[J]. Tech Vasc Interv Radiol, 2017, 20(3): 206-215. [19] JAIN N, SHEIKH M A, BAJAJ D, et al. Periprocedural complications with balloon pulmonary angioplasty: analysis of global studies[J]. JACC Cardiovasc Interv, 2023, 16(8): 976-983. [20] LANG I M, ANDREASSEN A K, ANDERSEN A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function[J]. Eur Heart J, 2023, 44(29): 2659-2671.